Jessica Fye
Stock Analyst at JP Morgan
(4.53)
# 261
Out of 5,124 analysts
219
Total ratings
62.77%
Success rate
16.05%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $16.51 | +57.48% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $31.74 | -21.24% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $12.93 | +77.88% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $170.00 | +17.06% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $67.30 | -3.42% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $29.49 | -15.23% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $95.20 | +26.05% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $397.65 | +18.95% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $21.74 | +249.59% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $98.77 | -9.89% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $59.43 | +100.24% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $213.24 | +23.80% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $453.36 | +16.90% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $303.81 | +26.72% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $79.11 | +1.13% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $46.55 | +11.71% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $78.99 | -2.52% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $27.98 | +25.09% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $174.04 | -22.43% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $487.25 | -32.27% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.80 | +66.67% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $34.60 | +44.51% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $31.54 | -4.88% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $42.28 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $12.36 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.70 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $13.96 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.85 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.15 | +508.70% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $28.93 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.72 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.77 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $16.51
Upside: +57.48%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $31.74
Upside: -21.24%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $12.93
Upside: +77.88%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $170.00
Upside: +17.06%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $67.30
Upside: -3.42%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $29.49
Upside: -15.23%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $95.20
Upside: +26.05%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $397.65
Upside: +18.95%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $21.74
Upside: +249.59%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $98.77
Upside: -9.89%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $59.43
Upside: +100.24%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $213.24
Upside: +23.80%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $453.36
Upside: +16.90%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $303.81
Upside: +26.72%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $79.11
Upside: +1.13%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $46.55
Upside: +11.71%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $78.99
Upside: -2.52%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $27.98
Upside: +25.09%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $174.04
Upside: -22.43%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $487.25
Upside: -32.27%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.80
Upside: +66.67%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $34.60
Upside: +44.51%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $31.54
Upside: -4.88%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $42.28
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $12.36
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.70
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $13.96
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.85
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.15
Upside: +508.70%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $28.93
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.72
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $15.77
Upside: -